Health care stocks were flat to lower pre-bell Monday, with The Health Care Select Sector SPDR Fund (XLV) unchanged and the iShares Biotechnology ETF (IBB) down 0.4%.
Corcept Therapeutics (CORT) shares were up over 93% after the company said its phase 3 trial of relacorilant plus nab-paclitaxel to treat a type of ovarian cancer met its primary goal.